1. Home
  2. LEN vs IQV Comparison

LEN vs IQV Comparison

Compare LEN & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lennar Corporation

LEN

Lennar Corporation

HOLD

Current Price

$118.63

Market Cap

31.0B

ML Signal

HOLD

Logo IQVIA Holdings Inc.

IQV

IQVIA Holdings Inc.

HOLD

Current Price

$221.58

Market Cap

36.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEN
IQV
Founded
1954
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.0B
36.4B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
LEN
IQV
Price
$118.63
$221.58
Analyst Decision
Hold
Buy
Analyst Count
17
17
Target Price
$125.13
$237.59
AVG Volume (30 Days)
10.1M
1.3M
Earning Date
12-16-2025
10-28-2025
Dividend Yield
1.68%
N/A
EPS Growth
N/A
N/A
EPS
10.16
7.30
Revenue
$34,766,213,000.00
$15,904,000,000.00
Revenue This Year
N/A
$6.14
Revenue Next Year
$3.19
$5.35
P/E Ratio
$11.75
$30.43
Revenue Growth
N/A
3.85
52 Week Low
$98.42
$134.65
52 Week High
$157.45
$234.30

Technical Indicators

Market Signals
Indicator
LEN
IQV
Relative Strength Index (RSI) 42.40 50.89
Support Level $117.04 $217.86
Resistance Level $122.79 $230.80
Average True Range (ATR) 3.67 5.33
MACD -0.97 -1.09
Stochastic Oscillator 12.05 39.49

Price Performance

Historical Comparison
LEN
IQV

About LEN Lennar Corporation

Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.

About IQV IQVIA Holdings Inc.

Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

Share on Social Networks: